Vitaliana De Sanctis
Overview
Explore the profile of Vitaliana De Sanctis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
1007
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
De Sanctis V, Facondo G, Vullo G, Anzellini D, Sanguineti G, Nardangeli A, et al.
Cancer Diagn Progn
. 2023 Mar;
3(2):194-200.
PMID: 36875316
Background/aim: To evaluate the outcome and toxicities in patients with locally advanced cervical cancer (LACC) treated with radiochemotherapy and intracavitary brachytherapy. Patients And Methods: This study included 67 patients with...
12.
De Felice F, Vicenzi L, Macchia G, Vavassori A, Perrucci E, Cerrotta A, et al.
Medicina (Kaunas)
. 2023 Feb;
59(2).
PMID: 36837584
: Exclusive radiotherapy, including external beam radiotherapy (EBRT) and interventional radiotherapy/brachytherapy (IRT/BT), with concurrent cisplatin-based chemotherapy, represents the standard of care in patients with locally advanced cervical cancer (LACC). The...
13.
Facondo G, Vullo G, De Sanctis V, Rotondi M, Sigillo R, Valeriani M, et al.
J Pers Med
. 2023 Feb;
13(2).
PMID: 36836463
Background: To evaluate clinical outcomes of stereotactic body radiation therapy (SBRT) as a local treatment for lymph node metastases from gynecological cancers. Methods: Between November 2007 and October 2021, we...
14.
Bari A, Gerardi C, Allocati E, Puzzovivo A, De Sanctis V, Tucci A, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497442
Compared to other patients suffering from hematological malignancies, classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) patients have a long life expectancy when in complete remission at the...
15.
Facondo G, Vullo G, De Sanctis V, Vitiello C, Nieddu L, Alfo M, et al.
J Contemp Brachytherapy
. 2022 Oct;
14(4):341-346.
PMID: 36199948
Purpose: To examine quality of life (QOL) and sexual functioning in a series of patients with intermediate- and high-intermediate risk endometrial cancer, treated with exclusive adjuvant one week high-dose-rate (HDR)...
16.
Valeriani M, Di Staso M, Facondo G, Vullo G, De Sanctis V, Gravina G, et al.
J Clin Med
. 2022 Aug;
11(16).
PMID: 36013023
Background: To evaluate outcomes in terms of survival and toxicity in a series of intermediate-risk prostate cancer (PCa) patients treated with hypofractionated radiotherapy (HyRT) + hormonal therapy (HT) with or...
17.
Perrucci E, Cerrotta A, Macchia G, Augurio A, Campitelli M, De Sanctis V, et al.
Crit Rev Oncol Hematol
. 2022 May;
174:103704.
PMID: 35533816
This survey investigated prognostic factors, treatment modalities, references followed and radiation oncologists' opinions to prescribe adjuvant therapy in early intermediate-risk cervical cancer. All but one recommended pelvic radiotherapy ± vaginal...
18.
Facondo G, Vullo G, De Sanctis V, Valeriani M, Ascolese A, Massaro M, et al.
Cancer Diagn Progn
. 2022 Apr;
1(2):53-60.
PMID: 35403131
Background: Standard treatment for locally advanced cervical cancer is external beam radiotherapy followed by brachytherapy (BT). Stereotactic body radiation therapy (SBRT) is a possible option for treating patients ineligible for...
19.
Di Molfetta S, Daniele A, Gerardi C, Allocati E, Minoia C, Loseto G, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326591
Background: Overall survival after lymphoma has improved in recent years, but the high prevalence of late treatment-related sequelae has been observed as a counterpart. Method: In this systematic review, FIL...
20.
Nassi L, De Sanctis V, Loseto G, Gerardi C, Allocati E, Ciavarella S, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158787
Background: The increase of lymphoma patient survival led to a modification of the incidence of long-term sequelae, including second malignancies (SM). Several groups have dealt with the incidence of SM,...